COVID-19, Immunosuppression
Conditions
Brief summary
In order to detect the immunosuppression status of COVID-19 patients, this study collected blood samples of COVID-19 patients on the 10th, 20th and 30th days after the onset of symptoms, and detected the proinflammatory, anti-inflammatory factors，immunosuppressive marker，immune cells in the blood samples to evaluate the immunosuppression status of COVID-19 patients.
Detailed description
After SARS-CoV-2 infection, the patient's immune system is overactivated. While the immune cells release a large number of proinflammatory factors, anti-inflammatory response starts at the same time. Anti-inflammatory factors such as IL-4, IL-10, and IL-37 will be compensated to resist the release of proinflammatory factors and prevent the further development of systemic inflammatory response. However, when the anti-inflammatory factor is excessively released, it will cause compensatory response syndrome, leading to immunosuppression. Whether the level of anti-inflammatory factors continues to rise, and whether it will lead to the persistence of later immunosuppression is unknown. Therefore, this study intends to recruit COVID-19 patients, detect the pro-inflammatory and anti-inflammatory factors，immunosuppressive marker，immune cells in 10 days, 20days, and 30days after the symptoms appear, and evaluate the immunosuppression status of patients with COVID-19
Interventions
DIAGNOSTIC_TESTmid covid-19 patients
Collect the patient's whole blood for testing
Sponsors
Qilu Hospital of Shandong University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participant is diagnosed with symptomatic COVID-19 by a positive PCR for SARS-CoV-2 or antigen quicktest. 2. Study participant is 18 years of age or older
Exclusion criteria
1. Patients with immunosuppression, including HIV infection, hematopoietic stem cell transplantation and high-dose immunosuppressant therapy 2. Pregnancy or breastfeeding 3. Patients receiving chemotherapy or other cancer treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The concentration of inflammatory markers (IL-1β、IL-2、 IL-2R 、IL-4 、 IL-6 、 IL-8、 IL-10 、IFN-γ、TNF-α 、VEGF, etc.) in peripheral blood. | 10, 20, 30days |
| The concentration of immunosuppression makers(HLA-DR, PD-1, TIM-3,etc.) in peripheral blood. | 10, 20, 30days |
| The number of immune cells(Th1/Th2 cell, Treg cell, MDSCs,etc.) in peripheral blood. | 10, 20, 30days |
Countries
China
Contacts
Primary ContactJiaojiao Pang, Dr
Outcome results
None listed